[go: up one dir, main page]

MXPA04005554A - Benzotiazoles. - Google Patents

Benzotiazoles.

Info

Publication number
MXPA04005554A
MXPA04005554A MXPA04005554A MXPA04005554A MXPA04005554A MX PA04005554 A MXPA04005554 A MX PA04005554A MX PA04005554 A MXPA04005554 A MX PA04005554A MX PA04005554 A MXPA04005554 A MX PA04005554A MX PA04005554 A MXPA04005554 A MX PA04005554A
Authority
MX
Mexico
Prior art keywords
lower alkyl
optionally substituted
pyran
dihydro
compounds
Prior art date
Application number
MXPA04005554A
Other languages
English (en)
Inventor
David Norcross Roger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA04005554A publication Critical patent/MXPA04005554A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84Naphthothiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de formula general (I), en la que R1 es el 3,6-dihidro-2H-piran-4-ilo, el 5,6-dihidro-4H-piran-3-ilo, el 5,6-dihidro-4H-piran-2-ilo, el tetrahidropiran-2-, -3- o -4-ilo, el ciclohex-2-enilo, el ciclohexilo o es el 1,2,3,6, tetrahidropiridi-4-ilo o piperidin-4-ilo, que estan opcionalmente sustituidos por C(O)CH3 en la posicion 2 del atomo de hidroxi o es fenil, opcionalmente sustituido por N; R2 es alquilo de bajo peso molecular, piperidin-1-ilo opcionalmente sustituido por -(CH2)n-N(R`)-C(O)- -(CH2)n-NR2`, -(CH2)n -o-alquilo de bajo peso molecular; o es morfolinilo o es piridinilo que esta opcionalmente sustituido por halogeno, -N(R`)- -(CH2)n-O-alquilo de bajo peso molecular, morfolinilo opcionalmente sustituido por halogeno. -NR1) -(CH2)n-O- alquilo inferior, alquilo inferior, alcoxi inferior, morofolinilo o -(CH2)n- pirrolidinilo; n es el numero 0, 1 o 2; R` es hidrogeno o alquilo de bajo peso molecular, y a sales de adicion de acido farmaceuticamente aceptables de los mismos. se ha constatado que los compuestos de la formula general I son ligandos del receptor de adenosina. De modo especifico, los compuestos de la presente invencion tienen buena afinidad con el receptor A2A y pueden utilizarse para el tratamiento de enfermedades relacionadas con este receptor.
MXPA04005554A 2001-12-12 2002-12-05 Benzotiazoles. MXPA04005554A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01129273 2001-12-12
PCT/EP2002/013769 WO2003053961A1 (en) 2001-12-12 2002-12-05 Benzothiazoles

Publications (1)

Publication Number Publication Date
MXPA04005554A true MXPA04005554A (es) 2004-09-10

Family

ID=8179487

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04005554A MXPA04005554A (es) 2001-12-12 2002-12-05 Benzotiazoles.

Country Status (21)

Country Link
US (1) US6734179B2 (es)
EP (1) EP1456202B1 (es)
JP (1) JP4283116B2 (es)
KR (1) KR100582696B1 (es)
CN (1) CN1286834C (es)
AR (1) AR037792A1 (es)
AT (1) ATE309242T1 (es)
AU (1) AU2002356628B2 (es)
BR (1) BR0214837A (es)
CA (1) CA2469876C (es)
DE (1) DE60207294T2 (es)
ES (1) ES2251628T3 (es)
GT (1) GT200200270A (es)
MX (1) MXPA04005554A (es)
PA (1) PA8561101A1 (es)
PE (1) PE20030751A1 (es)
PL (1) PL371064A1 (es)
RU (1) RU2293736C2 (es)
TW (1) TW200409772A (es)
UY (1) UY27578A1 (es)
WO (1) WO2003053961A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2301962T3 (es) * 2003-01-13 2008-07-01 F. Hoffmann-La Roche Ag Derivados de benzoxazol y su uso como ligandos de receptor de adenosina.
US6872833B2 (en) 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
EP1636223B1 (en) * 2003-05-19 2008-03-19 F. Hoffman-la Roche AG Benzothiazole derivatives as adenosine receptor ligands
AU2004241720B2 (en) * 2003-05-21 2008-11-06 F. Hoffmann-La Roche Ag Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine A2A receptor
KR20060058132A (ko) 2003-09-19 2006-05-29 에프. 호프만-라 로슈 아게 아데노신 수용체 리간드로서의 싸이아졸로피리딘 유도체
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
WO2008052930A2 (en) * 2006-11-03 2008-05-08 F. Hoffmann-La Roche Ag Preparation of 4-alk0xy-7- (tetrahydropyran-4-yl) benzothiazol-2-amine derivatives
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
AR117844A1 (es) * 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3374550D1 (en) 1982-12-21 1987-12-23 Johnsen Jorgensen Plastics Ltd Dispensing container
RU2041216C1 (ru) * 1991-04-04 1995-08-09 Эйсай Ко., Лтд. Производное бензотиазола или его фармакологически приемлемая соль
DE69833224T2 (de) 1997-11-10 2006-09-28 Bristol-Myers Squibb Co. Benzothiazole als protein tyrosin-kinase inhibitoren
CA2344828A1 (en) 1998-09-22 2000-03-30 Tomoyuki Kanda ¬1,2,4|triazolo¬1,5-c|pyrimidine derivatives
YU96502A (sh) * 2000-06-21 2006-01-16 F. Hoffmann-La Roche Ag. Derivati benzotiazola
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives

Also Published As

Publication number Publication date
PA8561101A1 (es) 2003-07-28
AU2002356628B2 (en) 2008-04-17
EP1456202B1 (en) 2005-11-09
KR100582696B1 (ko) 2006-05-23
RU2004121683A (ru) 2006-01-10
TW200409772A (en) 2004-06-16
DE60207294T2 (de) 2006-07-20
PL371064A1 (en) 2005-06-13
ATE309242T1 (de) 2005-11-15
ES2251628T3 (es) 2006-05-01
JP4283116B2 (ja) 2009-06-24
BR0214837A (pt) 2004-08-31
EP1456202A1 (en) 2004-09-15
AR037792A1 (es) 2004-12-01
GT200200270A (es) 2003-07-30
WO2003053961A1 (en) 2003-07-03
PE20030751A1 (es) 2003-09-05
DE60207294D1 (en) 2005-12-15
US6734179B2 (en) 2004-05-11
CA2469876A1 (en) 2003-07-03
UY27578A1 (es) 2003-06-30
CN1286834C (zh) 2006-11-29
RU2293736C2 (ru) 2007-02-20
CA2469876C (en) 2011-01-11
AU2002356628A1 (en) 2003-07-09
KR20040073473A (ko) 2004-08-19
CN1602310A (zh) 2005-03-30
JP2005521647A (ja) 2005-07-21
US20030144288A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
TW200407134A (en) Nicotin-or isonicotin benzothiazole derivatives
ATE540928T1 (de) Isochinolinverbindungen und ihre medizinische verwendung
TW200740760A (en) Malonamide derivatives
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
SE0104332D0 (sv) Therapeutic agents
MX2009002229A (es) Benzotriazoles como moduladores de cinasas.
EP1423111A4 (en) FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
JO2262B1 (en) Benzodiazepine derivatives
DE60236600D1 (de) Substituierte 1h-dihydropyrazole, ihre herstellung und verwendung
NZ533310A (en) Benzimidazoles useful as protein kinase inhibitors
TW200505903A (en) CGRP receptor antagonists
ATE437872T1 (de) Proteinkinaseinhibitoren
NO20054404L (no) 5,7-Diaminopyrazolo [4,3-D] Pyrimidiner Anvendelige ved behandling av of Hypertensjon
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
MXPA00006605A (es) Compuestos de carbonil-indol biciclicos como agentes antiinflamatorios/analgesicos.
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
DE60309057D1 (de) Azabicycloderivate als antagonisten des muscarinischen rezeptors
ATE357453T1 (de) Comt-inhibitoren
MXPA04005554A (es) Benzotiazoles.
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
TW200716547A (en) Piperidin-4-yl-amide derivatives
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
DK1256581T3 (da) Forebyggende eller terapeutiske midler til gastrisk eller ösofageal regurgitation
DE60330864D1 (de) Neue verbindungen, deren verwendung und herstellung

Legal Events

Date Code Title Description
FG Grant or registration